国联民生医药：小核酸风口之上：四重催化密集

Investment Rating - The report maintains a "Hold" rating for the pharmaceutical sector [7] Core Insights - The pharmaceutical industry is currently experiencing a shift towards innovation and international expansion, with significant growth expected in small nucleic acid therapies and supply chain management [5][4] - The report highlights the strong performance of CROs and certain upstream companies, indicating a positive trend in the market despite overall mixed performance in the pharmaceutical sector [3][4] - The report emphasizes the importance of clinical data releases in 2026, which could further validate the efficacy of small nucleic acid drugs and enhance market confidence [25][26] Summary by Sections Small Nucleic Acids - The commercialization of small nucleic acids is entering a high-growth phase, with notable sales increases for key products like Novartis' Leqvio and Alnylam's siRNA products [15][16] - The global transaction volume in the small nucleic acid sector surged to $36.5 billion in 2025, with major pharmaceutical companies actively acquiring small nucleic acid technology platforms [22] - Significant clinical data for small nucleic acid drugs is expected to be released in 2026, which could solidify their role in treating chronic diseases [25][26] Pharmaceutical Market Review - The pharmaceutical index increased by 0.14% during the week of February 2-6, outperforming both the ChiNext and CSI 300 indices [32][33] - The total trading volume in the pharmaceutical sector was approximately 475.5 billion yuan, accounting for 3.99% of the total market, which is below the historical average of 7.09% [46] - The report notes that the pharmaceutical sector's performance ranks 14th among all industries for the week, indicating a relatively stable position in the market [35] Investment Opportunities - The report suggests focusing on companies involved in small nucleic acids, particularly those with dual-target strategies and those that have successfully expanded internationally [31] - Key companies to watch include CROs like Tigermed and Baiyue, as well as small nucleic acid firms such as Reebio and Maiwei [4][31] - The report identifies three main investment directions: BD 2.0, small nucleic acids, and supply chain management, emphasizing the potential for high returns in these areas [5]